- iNCOVACC, the world’s first nasal vaccine to prevent COVID, has been approved by the Drug Controller General of India as a COVID booster dose.
- On November 28, 2022 Bharat Biotech International Limited has announced that its COVID-19 intranasal vaccine iNCOVACC (BBV154) has been approved by the Central Drugs Standard Control Organization (CDSCO) under ‘Restricted Emergency Use’ in India for ages 18 years and above.
- iNCOVACC, a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized SARS-CoV-2 spike protein, is the world’s first intranasal vaccine to receive both primary series and heterologous booster approval.
- Bharat Biotech’s intranasal vaccine is to be used as a heterologous booster dose against currently available COVID-19 vaccines.
First Nasal Vaccine against COVID- 19 approved
Click here for more Current Affairs